TURNSTONE BIOLOGICS CORP (TSBX) Stock Price, Quote, News and Summary
NASDAQ:TSBX - Nasdaq - US90042W1009 - Common Stock
TSBX Quote and Key Statistics
TURNSTONE BIOLOGICS CORP
NASDAQ:TSBX (1/21/2025, 8:00:02 PM)
After market: 0.435 -0.01 (-2.25%)0.445
+0 (+0.91%)
TSBX Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -127.24% | ||
| ROE | -170.52% | ||
| Debt/Equity | 0 |
TSBX Performance and Technical Analysis
TSBX Ownership and Analysts
TSBX Latest News and Analysis
Get insights into the top gainers and losers of Tuesday's after-hours session.
Get insights into the top gainers and losers of Tuesday's after-hours session.
Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
Portfolio Prioritization and Corporate Restructuring Extends Cash Runway into 2Q 2026
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Turnstone Biologics presents preclinical data highlighting potential for Selected TIL therapy in solid tumors at SITC 2024...
Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway
Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway
Turnstone Biologics announces strategic restructuring to prioritize portfolio and extend financial runway....
About TSBX
Company Profile
Turnstone Biologics Corp. operates as a clinical stage biotechnology company. The company is headquartered in La Jolla, California and currently employs 81 full-time employees. The company went IPO on 2023-07-21. The firm is focused on developing new medicines to treat and cure patients with solid tumors. The company is developing tumor infiltrating lymphocytes (TIL) therapies for the potential treatment of multiple solid tumors. The company is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. The company is advancing TIDAL-01, its lead Selected TIL product candidate, for the treatment of multiple solid tumor indications. TIDAL-01 utilizes an unbiased identification and functional screening process to isolate and selectively expand the greatest breadth of tumor-reactive TILs from the patient’s tumor. Its next Selected TIL program, TIDAL-02, is being designed to encompass a next generation streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function.
Company Info
TURNSTONE BIOLOGICS CORP
9310 Athena Circle, Suite 300
La Jolla CALIFORNIA US
Employees: 81
Company Website: https://www.turnstonebio.com
Investor Relations: https://ir.turnstonebio.com/
Phone: 13478975988
TSBX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.06 | 305.03B | ||
| AMGN | AMGEN INC | 14.3 | 147.72B | ||
| GILD | GILEAD SCIENCES INC | 20.98 | 115.85B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 839 | 110.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.14 | 75.58B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.18B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.28B | ||
| NTRA | NATERA INC | N/A | 22.11B | ||
| BIIB | BIOGEN INC | 8.63 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 16.43B |